PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP Tax Department 1735 Market Street, Suite 3100 Philadelphia, PA 19103
April 20, 2024
MEMORANDUM
TO: Marcus Whitfield, Vice President of Global Tax, Penterra Pharmaceuticals Corp.
CC: Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp. Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp. Sylvia Hartwell, Partner, Calderwood & Harkness LLP Garrett Simmons, Associate, Calderwood & Harkness LLP Leila Nazari, Associate, Calderwood & Harkness LLP
FROM: Leonard Cross, Partner, Tax Department, Calderwood & Harkness LLP
RE: Advance Pricing Agreement (APA) Considerations — Bilateral APA with IRS and Irish Revenue for Penterra Pharmaceuticals Corp. Transfer Pricing Arrangements (TY 2021 Forward)
Matter Number: 1018-00009
PRIVILEGE NOTICE: This memorandum is a privileged and confidential attorney-client communication and attorney work product prepared by Calderwood & Harkness LLP. It is intended solely for the use of the addressees identified above and should not be disclosed, distributed, or otherwise made available to any third party without the prior written consent of Calderwood & Harkness LLP. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.
Right-click to update Table of Contents
I. Executive Summary
This memorandum follows the successful resolution of the Internal Revenue Service Large Business & International Division ("LB&I") examination of the transfer pricing practices of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") for tax years 2017 through 2020 (Exam Team LB&I-NE-TP-2022-00641). The purpose of this memorandum is to analyze whether PPC should pursue a bilateral advance pricing agreement ("APA") with the IRS and the Irish Revenue Commissioners ("Irish Revenue") to achieve prospective certainty for the intercompany transfer pricing arrangements between PPC and its Irish subsidiary, Penterra Biopharma International DAC ("PBI").
As the members of PPC's management team are well aware, the recently concluded IRS examination resulted in proposed adjustments of $380.4 million across four categories of issues relating to the cost-sharing arrangement, legacy intellectual property royalties, and the economic substance of PBI. Through vigorous defense by Calderwood & Harkness LLP ("C&H") and Whitmore Valuation Group ("WVG"), the matter was resolved at IRS Appeals with a total adjustment of $47.6 million — representing only 12.51% of the originally proposed adjustments — pursuant to the Form 906 Closing Agreement executed on March 29, 2024. All proposed penalties under IRC § 6662(e) were fully abated.
The total cost of the examination to PPC was approximately $21.2 million, comprised of the following: federal income tax liability of approximately $10.0 million; interest of approximately $2.84 million; and professional fees of approximately $8.33 million. The professional fee component included C&H legal fees of $5,837,420, WVG economic and valuation consulting fees of $2,146,800, and Thornbury & Keogh ("T&K") Irish tax advisory fees of approximately $341,200. While the resolution was highly favorable — reflecting savings of approximately $83.0 million (an 86.6% reduction) versus the IRS's full proposed adjustment — the cost, management distraction, and uncertainty associated with the 22-month examination process were substantial.
Core Recommendation. C&H recommends that PPC seriously consider pursuing a bilateral APA covering the cost-sharing arrangement ("CSA"), the legacy IP royalty arrangement, and the Penterra Manufacturing Ireland ("PMI") contract manufacturing arrangement, for a prospective term beginning with tax year ("TY") 2025 (or TY 2024 if a rollback is feasible). The goal of the APA would be to avoid the cost, distraction, and uncertainty of future examinations on the same transfer pricing issues that were the subject of the recently resolved audit. The bilateral format — involving both the IRS and Irish Revenue — is essential to ensure that both jurisdictions accept the same transfer pricing methodology and to eliminate the risk of double taxation.
This memorandum addresses the following topics in detail:
(1) What an APA is and how it operates;
(2) The types of APAs available (unilateral, bilateral, and multilateral);
(3) The bilateral APA process with the IRS and Irish Revenue, including procedural requirements;
(4) The scope of the proposed APA for PPC;
(5) The advantages of pursuing a bilateral APA;
(6) The disadvantages and risks;
(7) Timing and cost estimates;
(8) Strategic considerations specific to PPC in light of the recent examination; and
(9) Recommended next steps for PPC's management team.
We note at the outset that this memorandum should be read in conjunction with two companion memoranda: the going-forward transfer pricing recommendations memorandum dated April 15, 2024, and the PBI substance enhancement recommendations memorandum dated April 22, 2024, both prepared by C&H and previously delivered to PPC's management.
II. Background — Summary of the Resolved Examination
Before turning to the APA analysis, we briefly summarize the intercompany arrangements that were the subject of the recently concluded IRS examination and the terms of the resolution. This context is important because it directly informs the scope, strategy, and potential leverage for a prospective APA.
A. The IP Structure Under Scrutiny
PPC's international tax structure, which was the focus of the IRS examination, centers on PBI, a designated activity company incorporated in Ireland on March 15, 2012 and tax-resident in Ireland. PBI is a wholly owned subsidiary of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a Luxembourg private limited liability company. PHL is treated as a disregarded entity for U.S. federal income tax purposes. PHL is in turn wholly owned by PPC, resulting in PBI being treated as a first-tier controlled foreign corporation of PPC for U.S. tax purposes.
Cost-Sharing Arrangement. Effective July 1, 2012, PPC and PBI entered into a qualified cost-sharing arrangement ("CSA") under Treas. Reg. § 1.482-7. Under the CSA, PBI acquired the rights to develop and exploit PPC's pharmaceutical intellectual property outside the Americas (i.e., in Europe, Asia-Pacific, Africa, and the Middle East) in exchange for (i) a platform contribution transaction ("PCT") payment of $312 million, paid at inception, representing PBI's buy-in to pre-existing intangible property, and (ii) ongoing cost-sharing payments based on PBI's share of reasonably anticipated benefits ("RAB") from the intangible development activities conducted under the CSA.
For the tax years at issue (TY 2017–2020), PBI's cost-sharing ratios ranged from 38.2% (TY 2017) to 42.7% (TY 2020) of total qualified research and development costs. The total qualified R&D cost pool grew from $487.3 million in TY 2017 to $598.4 million in TY 2020, reflecting PPC's substantial and increasing investment in its pharmaceutical pipeline. These ratios were determined by reference to the relative shares of reasonably anticipated benefits attributable to PBI's exploitation territories (non-Americas) and PPC's exploitation territories (Americas), as prescribed by the regulations.
Legacy IP Royalty Arrangement. Separate from the CSA, PBI licensed certain pre-2012 legacy compounds (i.e., compounds whose development had been substantially completed prior to the July 1, 2012 effective date of the CSA and that were therefore not subject to cost-sharing) from PPC under a separate intercompany license agreement. PBI paid a royalty rate of 4.5% of non-Americas net sales for these legacy compounds. Non-Americas net sales of legacy compounds declined from $814.6 million in TY 2017 to $624.1 million in TY 2020 as these older products moved through their lifecycle.
PMI Contract Manufacturing. Penterra Manufacturing Ireland ("PMI"), an Irish branch of PBI located at a manufacturing facility in Ringaskiddy, County Cork, Ireland, provides contract manufacturing services for biologic pharmaceutical products distributed in non-Americas markets. PMI operates under a contract manufacturing arrangement with PPC at a cost-plus markup of 8%, consistent with the arm's-length range for contract manufacturing services as determined by benchmarking analyses. PMI employs approximately 620 individuals at the Ringaskiddy facility.
Intermediate Holding Entity. As noted, PHL — the Luxembourg intermediate holding company — is a disregarded entity for U.S. federal income tax purposes. PHL holds 100% of the shares of PBI and is itself 100% owned by PPC. PHL was not a focus of the IRS examination, and its status as a disregarded entity means that transactions between PPC and PBI are analyzed as direct controlled transactions for U.S. transfer pricing purposes.
Key Products. The principal revenue-generating products for PPC and PBI during the examination period were:
• Veritaxol (oncology): Global revenues of approximately $3.12 billion in TY 2020, of which approximately $1.34 billion was generated in non-Americas markets by PBI;
• Imvara (immunology): Global revenues of approximately $1.87 billion in TY 2020, of which approximately $0.79 billion was generated in non-Americas markets; and
• Cerulon (rare disease): Global revenues of approximately $0.62 billion in TY 2020, of which approximately $0.28 billion was generated in non-Americas markets.
These three products collectively represent the substantial majority of PBI's revenue and are the primary drivers of the transfer pricing economics in both the CSA and the legacy IP royalty arrangement.
PBI Substance. PBI's operational substance in Ireland was a key issue in the examination, particularly in connection with the IRS's economic substance challenge. As documented extensively during the examination, PBI maintained significant and growing substance during the TY 2017–2020 period:
• PBI's employee headcount grew from 52 at inception in 2012 to 185 as of the end of TY 2020, including personnel responsible for regulatory affairs, commercial strategy, market access, medical affairs, and local management functions;
• PBI's principal office is located at Sandyford Business Park, Dublin, occupying approximately 18,000 square feet of dedicated office space;
• PBI's board of directors held 42 board meetings in Dublin during TY 2017–2020 (an average of more than 10 per year);
• PBI incurred cumulative regulatory expenditures of €47.2 million during TY 2017–2020, reflecting its active role in obtaining and maintaining marketing authorizations across 68 country markets outside the Americas;
• PBI exercises independent pricing authority across the 68 non-Americas country markets in which it distributes PPC's products; and
• PBI is managed on a day-to-day basis by its Managing Director, Aidan Naughton, who is resident in Ireland and reports to PPC's Chief Commercial Officer.
This substance profile was instrumental in defeating the IRS's economic substance challenge during the examination, and it will be equally important in supporting PBI's entitlement to residual profits under any APA methodology.
B. The IRS Examination and Resolution
The IRS opened its examination of PPC's transfer pricing for TY 2017–2020 on May 16, 2022, with the issuance of Letter 2205-A. The examination was conducted by the LB&I Transfer Pricing Practice, Northeast Division.
Proposed Adjustments. Over the course of the examination, the IRS proposed four categories of adjustments:
1. CSA Cost-Sharing Ratio Adjustments ($235.01 million): The IRS examination team contended that PBI's cost-sharing ratios should be increased to reflect a higher share of reasonably anticipated benefits, based on the IRS economist's alternative revenue projections and comparable profit-split methodologies. The IRS's proposed ratios ranged from approximately 45% to 52% for the examination years.
2. Legacy IP Royalty Rate Increase ($188.04 million): The IRS proposed increasing the legacy IP royalty rate from PPC's self-reported rate of 4.5% to 11.0% of non-Americas net sales, based on the IRS economist's selection of a different set of comparable uncontrolled transactions and a different statistical measure (mean versus median).
3. Economic Substance Challenge: The IRS initially challenged PBI's economic substance, asserting that PBI lacked sufficient employees, decision-making authority, and operational independence to be respected as the beneficial owner of the non-Americas IP rights. The IRS ultimately did not pursue this position to a formal notice of proposed adjustment ("NOPA"), effectively conceding the point in light of the substantial evidence of PBI's operations compiled through the IDR process.
4. Correlative Offset ($-42.65 million): A downward correlative adjustment offsetting a portion of the proposed upward adjustments, reflecting the mechanical interaction of the various adjustments.
The net proposed adjustment was $380.4 million, with a proposed IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million.
Examination Defense. C&H, in collaboration with WVG and T&K, defended PPC's transfer pricing positions throughout the examination process. The defense involved responding to 47 Information Document Requests ("IDRs") issued by the IRS between June 2022 and September 2023, preparing and submitting detailed legal and economic analyses refuting each proposed adjustment, responding to the NOPA, preparing a formal Protest filed on December 22, 2023, and representing PPC at the IRS Appeals conference on February 28, 2024 before Appeals Officer Noreen Castañeda.
Resolution. The examination was resolved at IRS Appeals on terms highly favorable to PPC. The total agreed adjustment was $47.6 million, representing only 12.51% of the IRS's proposed adjustments. The adjustment was allocated across the four tax years as follows: $11.2 million (TY 2017), $12.4 million (TY 2018), $12.8 million (TY 2019), and $11.2 million (TY 2020). The resulting federal income tax liability was approximately $10.0 million, with accrued interest of approximately $2.84 million. Critically, the proposed IRC § 6662(e) penalty of approximately $15.98 million was fully abated. The settlement was memorialized in a Form 906 Closing Agreement executed on March 29, 2024.
Total Cost. The total cost of the examination to PPC was approximately $21.2 million: $10.0 million in federal income tax, $2.84 million in interest, and approximately $8.33 million in professional fees ($5,837,420 in C&H legal fees; $2,146,800 in WVG economic consulting fees; and approximately $341,200 in T&K Irish advisory fees). The savings versus the IRS's full proposed adjustment (including penalties) were approximately $83.0 million, an 86.6% reduction.
C. Going-Forward Vulnerability
Notwithstanding the favorable resolution of the TY 2017–2020 examination, PPC remains exposed to the same transfer pricing scrutiny for TY 2021 and subsequent years. Several factors merit emphasis:
Continuation of the Same Structure. The CSA, legacy IP royalty arrangement, and PMI contract manufacturing arrangement remain in place and have not been substantively modified since the examination period. While C&H has separately recommended certain documentation and substance enhancements (see the companion memoranda dated April 15, 2024 and April 22, 2024), the fundamental economics of the intercompany transactions are materially unchanged.
IRS Interest. The IRS LB&I Transfer Pricing Practice, Northeast Division, has demonstrated a clear interest in PPC's structure. Given the magnitude of the proposed adjustments ($380.4 million) and the resources the IRS invested in the TY 2017–2020 examination, there is a meaningful probability that the IRS will select PPC for examination of TY 2021–2024 on the same issues. The IRS's transfer pricing enforcement priorities, as articulated in its annual focus areas, continue to emphasize CSAs, intangible-related transactions, and pharmaceutical industry structures.
No CAP Enrollment. PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for the TY 2017–2020 examination years and is not currently enrolled. CAP enrollment might provide some measure of contemporaneous resolution, but — as discussed further in Section X below — it does not provide the binding certainty of an APA.
Increasing Revenue Base. PPC's non-Americas revenues have continued to grow since TY 2020, driven by Veritaxol's ongoing commercial expansion and the launch of additional indications for Imvara. This growth increases the magnitude of the intercompany transactions at issue and, correspondingly, the dollar amount of any potential IRS adjustment.
An APA would address this ongoing vulnerability by providing prospective certainty and eliminating audit risk on the covered transactions for the APA term.
III. Overview of Advance Pricing Agreements
A. Definition and Purpose
An advance pricing agreement is a binding agreement between a taxpayer and one or more taxing authorities that establishes an agreed-upon transfer pricing methodology — or, in some cases, a specific arm's-length range or result — for specified controlled transactions for a fixed prospective period, typically five years. The APA concept is grounded in the recognition that transfer pricing is inherently uncertain and fact-intensive, and that prospective agreement on methodology can reduce compliance costs, promote certainty, and avoid resource-intensive controversies for both taxpayers and tax administrations.
In the United States, APAs are authorized under the broad authority of IRC § 482 and are administered by the Advance Pricing and Mutual Agreement Program ("APMA"), a specialized unit within the IRS LB&I Division. The procedural framework for APAs is set forth in Revenue Procedure 2015-41, which describes the process for requesting, negotiating, and executing APAs, as well as the obligations of taxpayers during the APA term, including annual compliance reporting.
The primary purposes of an APA are:
• Certainty: By establishing a mutually agreed transfer pricing methodology in advance, an APA eliminates the risk of future IRS examination and adjustment of the covered transactions during the APA term.
• Reduced Controversy Costs: An APA avoids the expense, management distraction, and uncertainty associated with transfer pricing examinations, including IDR responses, NOPA defenses, Protests, and Appeals proceedings.
• Avoidance of Double Taxation: In the bilateral or multilateral context, an APA ensures that two or more taxing jurisdictions accept the same transfer pricing methodology, preventing the imposition of tax on the same income by more than one jurisdiction.
• Administrative Efficiency: Both taxpayers and tax authorities benefit from the reduced administrative burden of prospective agreement as compared to retrospective examination and controversy.
B. Types of APAs
There are three types of APAs, each involving a different configuration of parties:
1. Unilateral APA. A unilateral APA is an agreement between the taxpayer and a single taxing authority — in PPC's case, the IRS alone. A unilateral APA binds only the IRS and PPC; it does not bind Irish Revenue or any other foreign tax authority. While a unilateral APA provides certainty for U.S. federal income tax purposes, it carries a significant risk of double taxation if the foreign jurisdiction disagrees with the methodology agreed upon in the unilateral APA. For PPC, this risk is particularly acute because PBI is subject to Irish corporation tax on its trading income, and any adjustment that increases PPC's U.S. income without a corresponding decrease in PBI's Irish income would result in double taxation.
2. Bilateral APA. A bilateral APA is an agreement involving the taxpayer and two taxing authorities — in PPC's case, the IRS and Irish Revenue. The bilateral APA is negotiated through the competent authority process established under the applicable income tax treaty — here, Article 25 (Mutual Agreement Procedure) of the U.S.-Ireland Income Tax Treaty (Convention between the Government of the United States of America and the Government of Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital Gains, signed November 28, 1997, as amended by Protocol signed January 24, 2013). A bilateral APA binds both jurisdictions and eliminates the risk of double taxation on the covered transactions. It is the preferred approach for transactions between related parties operating in two jurisdictions.
3. Multilateral APA. A multilateral APA involves three or more taxing jurisdictions. This format is appropriate where the intercompany transactions at issue involve related parties in three or more countries. In PPC's case, a multilateral APA is not likely to be necessary, given that the primary transfer pricing transactions at issue are between PPC (United States) and PBI (Ireland). PHL, the Luxembourg intermediate holding company, is a disregarded entity for U.S. purposes and does not independently engage in arm's-length transactions that would require Luxembourg competent authority involvement. However, if PPC's structure evolves to involve additional jurisdictions in a material way, a multilateral APA could be considered.
Recommendation. For the reasons discussed throughout this memorandum, C&H strongly recommends that PPC pursue a bilateral APA with the IRS and Irish Revenue. A unilateral APA would fail to address PBI's Irish tax position — including PBI's Knowledge Development box ("KDB") claims at the favorable 6.25% rate — and could create the risk of conflicting positions between the two jurisdictions. A bilateral APA, by contrast, provides certainty in both the United States and Ireland and ensures that the agreed methodology is applied consistently on both sides of the intercompany transactions.
C. Covered Transactions
For PPC, the APA would ideally cover the three principal categories of intercompany transactions between PPC and PBI:
1. The CSA Cost-Sharing Arrangement. The APA would establish the agreed methodology for determining PBI's cost-sharing payments under the CSA, including the formula for computing cost-sharing ratios based on reasonably anticipated benefits, the definition of the qualified R&D cost pool, and the treatment of any adjustments necessitated by changes in product mix or territory economics. This was the largest source of proposed IRS adjustments in the TY 2017–2020 examination ($235.01 million).
2. The Legacy IP Royalty Arrangement. The APA would establish the agreed methodology for determining the arm's-length royalty rate for pre-2012 legacy compounds licensed by PPC to PBI. This was the second-largest source of proposed IRS adjustments ($188.04 million). Given the IRS's aggressive position (11.0%) versus PPC's position (4.5%), obtaining prospective certainty on this issue is particularly valuable.
3. The PMI Contract Manufacturing Arrangement. Although the PMI arrangement was not a primary focus of the TY 2017–2020 examination, including it in the APA would provide comprehensive coverage of PPC's Irish intercompany transactions and eliminate any risk of future examination of the cost + 8% markup.
We note that the PCT payment itself ($312 million, paid in 2012) is a historical transaction and would not be directly covered by the APA. However, the APA methodology should be framed consistently with the PCT valuation and the underlying assumptions regarding PBI's exploitation rights, to avoid any inconsistency between the prospective APA and the historical buy-in.
IV. Advantages of Pursuing a Bilateral APA
The potential benefits of a bilateral APA for PPC are substantial and multifaceted. We discuss each category below.
A. Prospective Certainty on Transfer Pricing
The most significant advantage of an APA is the prospective certainty it provides. For the duration of the APA term — typically five years, with the possibility of a rollback to prior open years — PPC would have binding assurance that both the IRS and Irish Revenue accept the transfer pricing methodology applied to the covered transactions. This eliminates the audit risk on those transactions for the APA term.
The value of this certainty is substantial in PPC's case. The TY 2017–2020 examination resulted in proposed adjustments of $380.4 million, and the total cost to PPC — even after a highly favorable resolution — was approximately $21.2 million. If PPC were subjected to a similar examination for TY 2021–2024, the potential exposure and defense costs could be comparable or greater, given the growth in non-Americas revenues. An APA would eliminate this risk entirely for the covered years.
Moreover, prospective certainty has a direct and favorable impact on PPC's financial reporting. Under ASC 740-10 (formerly FIN 48), PPC is required to maintain reserves for uncertain tax positions. PPC's current FIN 48 reserve stands at $14.8 million, following the reduction from $62.4 million effected in connection with the March 29, 2024 settlement. An APA covering the CSA and royalty arrangements prospectively would provide a strong basis for further reducing or eliminating reserves attributable to transfer pricing positions for the covered prospective years, directly improving PPC's reported earnings and effective tax rate.
B. Elimination of Double Taxation Risk
A bilateral APA ensures that both the IRS and Irish Revenue accept the same transfer pricing methodology, preventing the imposition of tax on the same income by both jurisdictions. This is particularly critical for PPC given PBI's significant operations in Ireland and PBI's reliance on Ireland's Knowledge Development box regime, which provides a reduced 6.25% corporate tax rate on qualifying income derived from qualifying intellectual property.
Without a bilateral APA, any future U.S. adjustment to PPC's transfer pricing — whether arising from an IRS examination or from the application of the GILTI provisions — could result in additional U.S. tax without a corresponding reduction in PBI's Irish tax liability. Obtaining a correlative adjustment from Irish Revenue through the Mutual Agreement Procedure after the fact is possible but uncertain, time-consuming, and burdensome. A bilateral APA avoids this problem by establishing the agreed methodology ex ante, with both competent authorities bound to the result.
The U.S.-Ireland Income Tax Treaty's MAP provisions under Article 25 provide the treaty framework for the competent authority negotiation that underlies the bilateral APA process. These provisions are well-established and have been successfully utilized in numerous bilateral APAs between the U.S. and Ireland.
C. Reduced Compliance and Controversy Costs
The recently concluded examination consumed approximately $8.33 million in professional fees across three firms (C&H at $5,837,420; WVG at $2,146,800; and T&K at approximately $341,200). Beyond the direct financial cost, the examination required approximately 22 months of sustained engagement, during which PPC's tax department — led by Marcus Whitfield — and General Counsel's office — led by Deborah Staines — were required to devote significant management attention to responding to 47 IDRs, reviewing and commenting on economic analyses, participating in strategic conferences, and preparing for and attending the Appeals conference.
An APA, once in place, dramatically reduces the likelihood of any future IRS examination of the covered transactions. While the APA requires annual compliance reporting (discussed in Section VI.D below), the compliance report process is a modest administrative exercise compared to the burden of a full-scope examination. Over the five-year prospective term of a typical APA, the avoidance of even one examination cycle would more than offset the cost of the APA process itself.
D. Favorable Investor and Lender Perception
PPC's transfer pricing arrangements and associated tax contingencies are monitored by key stakeholders, and an APA would provide tangible benefits in this regard.
Institutional Shareholders. Ridgeview Capital Management LP, which holds an 8.3% institutional stake in PPC (Managing Partner Douglas Everett), actively monitors PPC's FIN 48 disclosures and tax contingencies as reported in PPC's SEC filings. Ridgeview has historically engaged PPC's investor relations team regarding the magnitude of uncertain tax position reserves and the potential for adverse examination outcomes. An APA would provide a credible basis for reducing these reserves and would demonstrate proactive management of transfer pricing risk, thereby improving investor confidence.
Lenders. Hargrove National Bank, N.A. (SVP Christine Bellucci), serves as administrative agent under PPC's $1.5 billion revolving credit facility. The credit agreement includes tax-indemnity and material-tax-event covenants that could be triggered by a significant adverse transfer pricing adjustment. An APA reduces the likelihood of triggering these covenants by providing certainty regarding the covered transactions.
SEC Disclosures. PPC's Form 10-K and Form 10-Q filings include disclosures regarding income tax contingencies and transfer pricing risk. An APA would improve PPC's disclosure posture by enabling the Company to disclose that prospective certainty has been obtained for the covered transactions, reducing the perceived risk profile of PPC's international tax structure.
E. Potential Rollback
Under Rev. Proc. 2015-41, a taxpayer may request that the transfer pricing methodology agreed upon in the APA be applied to prior open years (referred to as "rollback years"). For PPC, the potential rollback period would include TY 2021 through TY 2024 — i.e., the tax years that are not covered by the Form 906 Closing Agreement (which covered only TY 2017–2020) and that remain open under the applicable statute of limitations.
A rollback would provide additional certainty for these transition years and would eliminate the risk that the IRS could open a new examination of TY 2021–2024 covering the same transfer pricing issues. Given that PPC's methodology has not substantively changed since the examination period, a rollback is a realistic possibility, though it requires the agreement of both competent authorities and PPC's consent.
The strategic value of a rollback is significant: if granted, it would provide PPC with continuous transfer pricing certainty from TY 2021 through TY 2029 — a full nine-year period — effectively closing the window of vulnerability between the end of the Closing Agreement period and the start of the prospective APA term.
V. Disadvantages and Risks of Pursuing a Bilateral APA
While the advantages of a bilateral APA are compelling, PPC should also carefully consider the disadvantages and risks associated with the process. We address each category below.
A. Significant Time Investment
Bilateral APAs are complex undertakings that typically require two to four years to negotiate and finalize. IRS APA Program statistics indicate that the median completion time for bilateral APAs has ranged from approximately 33 to 40 months in recent years, and some bilateral APAs — particularly those involving complex cost-sharing arrangements or novel issues — have taken longer.
The time investment is driven by several factors: the preparation of the APA request submission (which requires extensive data compilation, economic analysis, and legal drafting); the IRS APMA team's review and due diligence process (which frequently involves supplemental data requests and follow-up questions); and the competent authority negotiation between the IRS and Irish Revenue (which involves multiple rounds of position papers, data exchanges, and meetings, and which is subject to scheduling constraints on both sides).
For PPC, this time investment will require sustained engagement from C&H, WVG, and T&K, as well as ongoing participation by PPC's tax department and General Counsel's office. While the workload is more evenly distributed over the APA period than the concentrated intensity of an examination defense, it nonetheless represents a meaningful commitment of management time and professional resources.
B. Substantial Cost
The estimated professional fees for a bilateral APA of the complexity contemplated for PPC are in the range of $2.0 million to $4.0 million, encompassing the following components:
• C&H legal fees for APA negotiation and management: $1.2 million to $2.5 million over the two-to-four-year negotiation period;
• WVG economic analysis fees (updating existing CUT, CPM/TNMM, and DCF analyses and preparing the APA economic submission): $500,000 to $1.0 million;
• T&K Irish coordination and Irish Revenue engagement fees: €200,000 to €400,000 (approximately $220,000 to $440,000 at current exchange rates); and
• IRS APA user fee: currently $113,500 for large taxpayers (subject to change under future IRS guidance).
Irish Revenue does not currently charge a formal user fee for bilateral APA or MAP engagements, but the Irish process requires dedicated engagement and preparation, which is reflected in T&K's estimated fees.
The total estimated cost is therefore in the range of $2.5 million to $4.5 million over the APA negotiation period. However, as discussed in Section IX below, this cost compares favorably to the $8.33 million in professional fees incurred in the TY 2017–2020 examination alone, particularly when the avoided tax and interest exposure is also considered. If the APA prevents even one future examination cycle, the investment is highly cost-effective.
C. Disclosure of Proprietary Information
The APA process requires extensive disclosure to both the IRS and Irish Revenue of PPC's business plans, revenue projections, cost structures, IP development strategies, product pipeline, and economic analyses. The APA request submission under Rev. Proc. 2015-41 is a comprehensive document that provides the tax authorities with a detailed window into the taxpayer's operations and economics.
While APA submissions are covered by the confidentiality protections of IRC § 6103 (which prohibits unauthorized disclosure of tax return information, including APA submissions) and the specific confidentiality provisions of Rev. Proc. 2015-41, Section 11, PPC should be aware that the IRS APMA team will have detailed insight into the Company's operations, financial projections, and strategic plans.
There is a residual concern that information disclosed during the APA process could inform the IRS's approach to non-covered transactions or years outside the APA term. For example, the financial projections and cost structures provided in the APA submission could be used by the IRS in unrelated examinations or by other divisions within LB&I. While the APMA program operates with a degree of independence from the examination function, the Chinese wall between these functions is not absolute, and PPC should factor this consideration into its decision-making.
That said, the IRS already has extensive knowledge of PPC's structure, operations, and economics from the recently concluded examination, during which 47 IDRs were answered and voluminous documentation was provided. The incremental disclosure associated with the APA process may therefore be limited.
D. Binding Nature
An APA is binding for its term. Once executed, PPC is obligated to apply the agreed transfer pricing methodology for each year of the APA term and to file annual compliance reports demonstrating adherence to the agreed methodology and the continued validity of the critical assumptions.
If PPC's business or IP structure changes materially during the APA term — for example, due to the launch of significant new products, the restructuring of PBI's operations, changes in cost-sharing ratios driven by shifts in the territorial revenue mix, or the acquisition or divestiture of IP assets — PPC may need to seek an amendment to or cancellation of the APA. The amendment and cancellation procedures under Rev. Proc. 2015-41 are available but can be complex and time-consuming, and there is no guarantee that the competent authorities will agree to modifications that PPC might request.
PPC should carefully evaluate whether any anticipated changes in its product portfolio (including the lifecycle trajectory of Veritaxol, pipeline compounds under development, and potential therapeutic area expansions or contractions), corporate structure (including any potential restructuring of the PPC-PHL-PBI chain), or geographic market strategy could render the APA methodology inapplicable or disadvantageous during the proposed term.
E. No Guarantee of Favorable Terms
The APA process is a negotiation, and the outcome is not predetermined. The IRS and Irish Revenue may not agree to the exact methodology that PPC proposes. The bilateral negotiation process involves give-and-take, and the final APA may incorporate compromises that differ materially from PPC's preferred approach.
Of particular concern, the IRS APMA team may seek to incorporate elements of the IRS's positions from the TY 2017–2020 examination into the APA negotiation — for instance, by advocating for higher cost-sharing ratios, different comparable selection criteria for the CUT analysis, or a different discount rate for the DCF methodology. While the favorable Closing Agreement resolution validates PPC's overall approach, the settlement was a compromise (12.51% of proposed adjustments), and the IRS could argue that the compromise implicitly supports a methodology that yields a result somewhere between PPC's self-reported positions and the IRS's original proposed adjustments.
There is also a risk that the APA negotiations could result in a methodology less favorable than PPC's current self-determined positions. In other words, by entering the APA process, PPC might effectively concede ground that it could otherwise defend successfully in a future examination. This risk must be weighed against the certainty value of the APA: the question is whether the certainty of a modestly less favorable methodology is preferable to the uncertainty of potentially facing aggressive IRS positions in a future audit.
F. Potential Signal to IRS
Filing an APA request signals to the IRS that PPC recognizes transfer pricing risk in its structure and is seeking prospective certainty. While this is a rational and legitimate business decision, there is a practical concern that the APA filing could be perceived by the IRS examination function as an implicit acknowledgment that PPC's positions are not fully defensible. This perception, even if unfounded, could contribute to heightened scrutiny of non-covered transactions or years outside the APA term.
Conversely, several countervailing considerations mitigate this concern. First, the IRS APA Program operates with a degree of institutional separation from the examination function, and APA filings are not routinely shared with examination teams. Second, the IRS already possesses extensive knowledge of PPC's structure from the recently concluded examination, so the marginal information conveyed by an APA filing is limited. Third, the IRS affirmatively encourages taxpayers to pursue APAs as a means of resolving transfer pricing disputes prospectively, and APA filings are a routine feature of large-taxpayer compliance. Filing an APA request is not, in itself, an unusual or suspicious action.
VI. Procedural Overview — Bilateral APA Process
This section provides a more detailed overview of the procedural steps involved in pursuing a bilateral APA with the IRS and Irish Revenue.
A. IRS APA Program (Rev. Proc. 2015-41)
The IRS APA process is administered by the APMA program within LB&I and proceeds through the following stages:
1. Pre-Filing Conference. The first formal step in the APA process is a pre-filing conference with the IRS APMA program. PPC and C&H would submit a written request for a pre-filing conference, identifying (at PPC's election) the taxpayer on an anonymous or identified basis. The pre-filing conference is an informal, confidential meeting with APMA staff that allows for a preliminary discussion of the proposed covered transactions, the proposed transfer pricing methodology, the proposed APA term, and any threshold issues that might affect the viability of the APA request.
The pre-filing conference serves several important functions: it allows PPC to gauge the IRS's receptivity to an APA covering the specific transactions at issue; it provides an opportunity to identify potential obstacles or areas of disagreement at an early stage; and it helps PPC refine its APA request before investing the substantial resources required to prepare the full submission. The pre-filing conference is not binding on either party, and PPC is free to decide not to proceed with the APA request following the pre-filing conference.
2. APA Request (Form 14661). Following the pre-filing conference, and assuming PPC decides to proceed, PPC would file a formal APA request with the APMA program using IRS Form 14661 (Application for Advance Pricing Agreement). The APA request is a comprehensive submission that includes the following components:
• A detailed description of the controlled transactions proposed to be covered by the APA, including the CSA cost-sharing arrangement, the legacy IP royalty arrangement, and (potentially) the PMI contract manufacturing arrangement;
• The proposed transfer pricing methodology for each covered transaction — for example, the comparable uncontrolled transaction ("CUT") method for the legacy IP royalties, the income method / Discounted cash flow ("DCF") approach for validating the CSA cost-sharing split, and the cost-plus method for PMI contract manufacturing;
• A comprehensive functional analysis of PPC and PBI, describing each entity's functions performed, assets employed, and risks assumed in connection with the covered transactions;
• An economic analysis with benchmarking data, building on and updating WVG's existing work, including the 14 CUT comparables for the royalty analysis, the 22 CPM/TNMM comparables for the supplemental benchmarking, and the DCF analysis utilizing a weighted average cost of capital ("WACC") of 9.8%;
• The proposed APA term (C&H recommends five years prospective, e.g., TY 2025–2029, with a rollback request for TY 2021–2024);
• Financial projections for PPC and PBI for the proposed APA term, including revenue forecasts, cost projections, and profitability estimates;
• A description of the proposed critical assumptions — the factual and legal premises upon which the APA methodology is based, the violation of which could trigger renegotiation or cancellation of the APA; and
• Payment of the applicable user fee (currently $113,500 for large taxpayers).
3. IRS Evaluation and Due Diligence. Upon receipt of the APA request, the APMA team assigns an APA team leader and team economist to the case. The APMA team reviews the submission in detail, conducts its own independent economic analysis, and may issue supplemental information requests to PPC. The due diligence phase can take several months to a year, depending on the complexity of the issues and the responsiveness of the parties.
4. Competent Authority Negotiation. For a bilateral APA, the IRS competent authority (a function housed within the APMA program) initiates negotiations with the Irish Revenue competent authority under Article 25 of the U.S.-Ireland Income Tax Treaty. The competent authority negotiation is a government-to-government process in which the two taxing authorities exchange position papers, data analyses, and proposed terms. The negotiations may involve multiple rounds of written exchanges and in-person or virtual meetings. PPC does not directly participate in the competent authority negotiations but is kept informed by C&H and APMA of the general progress and any requests for additional information.
5. Draft APA Agreement. Once the competent authorities reach agreement on the transfer pricing methodology and terms, a draft APA agreement is prepared. The draft is shared with PPC for review and comment. The APA agreement sets forth the covered transactions, the agreed methodology, the APA term, the critical assumptions, and the annual compliance reporting obligations.
6. Execution. The final APA is executed by PPC, the IRS, and (through the competent authority process) Irish Revenue. Upon execution, PPC is obligated to apply the agreed methodology for each year of the APA term and to file annual compliance reports as described in Section VI.D below.
B. Irish Revenue APA/MAP Process
On the Irish side, the competent authority process is administered by the Large Cases Division of the Irish Revenue Commissioners. Ireland has a well-established practice of engaging in bilateral APAs, particularly with the United States, and Irish Revenue is generally supportive of bilateral APAs where the Irish entity demonstrates sufficient operational substance to justify its entitlement to trading income.
PBI's substance profile — 185 employees, dedicated office space at Sandyford Business Park, 42 board meetings in Dublin during TY 2017–2020, €47.2 million in cumulative regulatory expenditures, independent pricing authority across 68 markets, and the leadership of Managing Director Aidan Naughton — is strong and well-documented. This substance profile supports PBI's entitlement to trading income treatment at the standard 12.5% Irish corporation tax rate, as well as the reduced 6.25% rate under the Knowledge Development box regime for qualifying intellectual property income.
Coordination with Ciarán Thornbury at Thornbury & Keogh (22 Fitzwilliam Square, Dublin 2, D02 YH68) will be essential for managing the Irish Revenue engagement. T&K has an established relationship with the Large Cases Division and is well-positioned to present PBI's case in the bilateral APA context. T&K would be responsible for preparing the Irish-side submission materials, coordinating with Irish Revenue on data requests and meetings, and ensuring that the APA methodology is consistent with PBI's Irish tax positions.
Irish Revenue will conduct its own independent review of PBI's functions, assets, and risks, and will seek assurance that the APA methodology is consistent with PBI's entitlement to an appropriate share of the combined profits of the PPC-PBI structure. In particular, Irish Revenue will want to ensure that the APA does not erode Ireland's tax base by attributing an inappropriately small share of income to PBI. This is a legitimate and expected concern, and the bilateral negotiation process is designed to balance the interests of both jurisdictions.
C. Rollback Provisions
Under Rev. Proc. 2015-41, PPC may request that the transfer pricing methodology agreed upon in the APA be applied retroactively to prior open years — the "rollback" years. For PPC, the potential rollback period would include TY 2021 through TY 2024, which are the tax years falling between the end of the period covered by the Form 906 Closing Agreement (TY 2017–2020) and the proposed start of the prospective APA term (TY 2025).
A rollback is not automatic; it requires the agreement of both competent authorities and PPC's affirmative consent. The rollback negotiation is typically conducted as part of the overall bilateral APA negotiation, and the competent authorities will evaluate whether the agreed methodology is appropriate for the rollback years given the facts and circumstances of those years.
The strategic advantage of a rollback for PPC is substantial. If the IRS were to open a new examination of TY 2021–2024 covering the same transfer pricing issues, PPC would face many of the same costs and uncertainties experienced in the TY 2017–2020 examination. A rollback would eliminate this risk by applying the APA methodology to the rollback years, effectively providing continuous coverage from TY 2021 through the end of the prospective APA term.
D. Annual Compliance Reports
For each year of the APA term (including any rollback years), PPC is required to file an annual APA compliance report with the APMA program. The compliance report is typically due by the extended filing deadline for the relevant tax return (i.e., October 15 for a calendar-year corporate taxpayer that has obtained an extension). The compliance report serves two primary functions:
• It demonstrates that PPC has applied the agreed transfer pricing methodology for the relevant tax year in accordance with the terms of the APA; and
• It confirms that the critical assumptions underlying the APA remain valid and have not been materially violated.
If a critical assumption is violated — for example, if PBI's employee headcount falls below a specified threshold, or if a material restructuring of the PPC-PBI structure occurs — PPC is required to notify the APMA program promptly. Depending on the nature and severity of the violation, the APA may need to be renegotiated, amended, or cancelled.
The annual compliance report is a relatively modest administrative exercise compared to the burden of a full-scope transfer pricing examination. C&H and WVG would assist PPC in preparing the compliance reports, and PPC's engagement with Crestfield & Associates (PPC's independent auditor) would include coordination on the treatment of the APA for financial reporting purposes.
VII. Scope of the Proposed APA
A. Covered Transactions
Based on our analysis of PPC's intercompany arrangements and the issues raised during the TY 2017–2020 examination, C&H recommends that the APA cover the following three categories of controlled transactions:
1. CSA Cost-Sharing Arrangement. The APA would establish the agreed methodology for determining PBI's cost-sharing payments under the CSA between PPC and PBI. Specifically, the APA would address:
• The formula for computing the reasonably anticipated benefit split between PPC (Americas) and PBI (non-Americas), including the revenue metrics, time horizons, and discount rates used to project relative benefits;
• The definition and composition of the qualified R&D cost pool, including which categories of expenditures are included and excluded;
• The treatment of adjustments required by changes in product mix, territory economics, or the relative commercial success of different products in different markets; and
• The arm's-length range for the cost-sharing ratio, taking into account the variability inherent in projecting reasonably anticipated benefits.
For reference, in TY 2020, the total qualified R&D cost pool was $598.4 million, and PBI's share was 42.7% ($255.52 million). The CSA cost-sharing adjustments were the largest category of proposed IRS adjustments in the recent examination ($235.01 million out of $380.4 million total).
2. Legacy IP Royalty. The APA would establish the agreed methodology for determining the arm's-length royalty rate applicable to the pre-2012 legacy compounds licensed by PPC to PBI. PPC's current position, which was substantially validated by the examination settlement, is a royalty rate of 4.5% of non-Americas net sales. This rate is supported by WVG's CUT analysis, which identified 14 comparable uncontrolled pharmaceutical license agreements with an interquartile range of 3.1% to 6.8% and a median of 4.4%.
The IRS's examination position — a royalty rate of 11.0% — was rejected by Appeals, and the settlement effectively validated a rate close to PPC's self-reported 4.5%. The APA would seek to formalize this result prospectively, ideally establishing a methodology (CUT method with an agreed comparable set) that produces a royalty rate within the arm's-length range supported by the comparable data.
3. PMI Contract Manufacturing. C&H recommends that PPC consider including the PMI contract manufacturing arrangement in the APA, even though this transaction was not a primary focus of the TY 2017–2020 examination. Including the PMI arrangement would provide comprehensive coverage of PPC's intercompany transactions with its Irish operations and would eliminate any future audit risk associated with the cost + 8% markup. PMI's manufacturing operations at Ringaskiddy, County Cork — with approximately 620 employees — represent a significant operational footprint, and the cost-plus methodology is well-established and should be readily defensible in the APA context.
B. Proposed Term
C&H recommends the following term structure for the proposed APA:
Prospective Term: Five years (TY 2025 through TY 2029), consistent with standard APA practice under Rev. Proc. 2015-41. A five-year prospective term provides a meaningful period of certainty while allowing PPC the flexibility to reassess its structure and methodology at the conclusion of the term. If the APA is successful, PPC could seek a renewal for an additional five-year term upon expiration.
Rollback: PPC should request a rollback of the APA methodology to TY 2021 through TY 2024 (four years), covering the period between the end of the Closing Agreement years (TY 2017–2020) and the start of the prospective APA term. As discussed in Section VI.C above, a rollback requires the agreement of both competent authorities.
Total Coverage: If the rollback request is approved, the APA would provide a total of nine years of coverage (TY 2021 through TY 2029), eliminating transfer pricing uncertainty for the entire period following the Closing Agreement.
C. Proposed Methodology
For each covered transaction, C&H recommends proposing the following methodologies, consistent with the approaches successfully employed in the TY 2017–2020 examination defense:
CSA. The income method / Discounted cash flow approach for validating the cost-sharing split, utilizing a weighted average cost of capital consistent with pharmaceutical industry benchmarks. In the TY 2017–2020 examination defense, PPC and WVG utilized a WACC of 9.8%, which was supported by extensive analysis of PPC's capital structure and industry-specific data. The reasonably anticipated benefits would be determined based on projected revenue splits by territory (Americas versus non-Americas), with appropriate adjustments for product lifecycle, pipeline expectations, and market-specific factors.
Royalty. The comparable uncontrolled transaction method, based on an agreed set of comparable uncontrolled pharmaceutical license agreements. The initial comparable set would build on WVG's existing database of 14 CUT comparables, with provision for periodic updating of the comparable set to reflect newly available data and market changes during the APA term.
PMI. The cost-plus method with an agreed markup percentage. The current cost + 8% markup would be proposed as the starting point, supported by benchmarking data from WVG's existing analyses of comparable contract manufacturing arrangements.
D. Critical Assumptions
The APA would be subject to a set of critical assumptions — the factual and legal premises upon which the agreed methodology is based. If any critical assumption is materially violated, PPC would be required to notify the APMA program, and the APA might need to be renegotiated or cancelled. C&H anticipates that the critical assumptions for PPC's APA would include the following:
• PBI's operational substance (including employee headcount, Dublin office operations, independent decision-making authority, and development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions) remains at current or enhanced levels throughout the APA term;
• No material restructuring of the PPC-PBI-PMI structure occurs during the APA term (e.g., no change in PBI's tax residence, no significant transfer of IP rights, no dissolution or merger of PBI);